

Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 144 243
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 84308459.1

(51) Int. Cl.⁴: A 61 K 31/485

(22) Date of filing: 05.12.84

(30) Priority: 06.12.83 GB 8332556

(71) Applicant: RECKITT AND COLMAN PRODUCTS LIMITED
P.O. Box 26 1-17, Burlington Lane
London W4 2RW(GB)

(43) Date of publication of application:
12.06.85 Bulletin 85/24

(72) Inventor: Lewis, John William
Ferries Corner Station Road
North Ferriby North Humberside(GB)

(84) Designated Contracting States:
BE CH DE FR IT LI LU NL SE

(72) Inventor: Lloyd-Jones, John Gareth
17 Arras Drive
Cottingham North Humberside(GB)

(74) Representative: Hardisty, David Robert et al,
BOULT, WADE & TENNANT 27 Furnival street
London EC4A 1PQ(GB)

(54) Analgesic compositions.

(57) An analgesic composition in parenteral or sublingual dosage form comprising an active dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine. Preferably the parenteral dosage form contains naloxone and buprenorphine within the weight ratio of 1:3 to 1:1 and the sublingual form within the ratio 1:2 to 2:1.

Analgesic Compositions

This invention relates to analgesic compositions and more particularly to compositions containing buprenorphine.

Buprenorphine (International Non-proprietary Name for N-cyclopropylmethyl-7 α -[1-(S)-hydroxy-1,2,2-trimethyl-propyl]6,14-endoethano-6,7,8,14-tetrahydronororipavine) has been shown in clinical trials to be a potent antagonist analgesic lacking the psychotomimetic effects found with other antagonist analgesics. Buprenorphine effectively relieves moderate to severe pain in doses of 0.1mg or more administered either parenterally or sublingually. The optimum therapeutic range for single doses is 0.3mg - 0.6mg by injection and 0.1mg - 0.4mg for sublingual tablets.

In animal tests and in man buprenorphine has been shown to have both agonist (morphine-like) and antagonist properties. However from direct dependence studies in animals and in man it has been concluded that buprenorphine does not produce significant physical dependence and the potential to produce psychological dependence is low as indicated by animal self administration studies and by the measurement of euphorogenic effects in human post addicts.

In man the agonist and narcotic antagonist characteristics of buprenorphine have been demonstrated in opiate addicts. In a study in Hong Kong oral buprenorphine in the dose range 6-16mg precipitated abstinence in opiate addicts presenting for detoxification. On the other hand in a study involving subjects stabilised on a relatively low daily dose of oral methadone, sublingual buprenorphine could be substituted for methadone with only a low level of

discomfort. In this situation buprenorphine was behaving as an opiate agonist of low intrinsic activity.

This limited ability of buprenorphine to substitute for the opiates and its low-level opiate-like euphorogenic effects makes buprenorphine acceptable to some opiate misusers particularly when their favoured opiates are unavailable, and this has led to some illicit use of the drug. As will be discussed below the compositions of the present invention provide a means of enhancing the 10 abstinence-precipitating properties of buprenorphine, and thus the aversive characteristics, without compromising its analgesic effect.

Preparations have been developed which protect the oral preparations of certain opioids from parenteral abuse by 15 the incorporation of naloxone. These preparations are based on the low oral bio-availability (~1%) of the narcotic antagonist naloxone (naloxone, chemically known as 1-N-allyl-14-hydroxynordihydromorphenone) when compared to that of methadone (~50%) and pentazocine (~30%). Thus a 20 significant quantity of naloxone can be introduced into oral preparations of these central analgesics without compromising their analgesic effect. If the opioid-naloxone preparations are dissolved in water and injected the naloxone is active and shows its narcotic antagonist 25 activity. It thus blocks the euphorogenic activity of the opioid and eliminates the development of psychological dependence. The inhibition of opiate effects by naloxone also prevents the development of physical dependence. U.S. Patent No. 3773955 to Pachter and Gordon describes the

oral combination of naloxone with a number of opiates particularly methadone.

There are also examples in which naloxone has been incorporated into oral preparations of opioids to prevent primary oral abuse. The combination of tilidine and naloxone affords such an example. Tilidine acting through a metabolite is more potent when given by the oral route than the parenteral route. Consequently no advantage can be gained by the addict in self administration of tilidine by injection and as such the observed abuse of tilidine has been by oral administration. A product containing naloxone was introduced to protect tilidine against this abuse.

To our knowledge there is no reference in the scientific or patent literature to the incorporation of naloxone (for purposes of abuse prevention) into formulations of opioids for parenteral or sublingual administration.

It will be appreciated from the foregoing discussion that when naloxone is combined with an opioid for parenteral administration, the effects of the opioid including its analgesic effect would be expected to be reduced. The literature on the pharmacology of buprenorphine would lead one to conclude that this would be true of buprenorphine. The interaction between buprenorphine and a specific opiate antagonist, diprenorphine when co-administered parenterally has been reported (Cowan et al., Br. J. Pharmacol., 60, 537 (1977)) to result in a reduction in the analgesic potency of buprenorphine by a factor of 300. It would therefore not have been expected that any combination of buprenorphine

with naloxone for parenteral administration could be found which would contain sufficient naloxone to be effective in limiting misuse, and would leave the analgesic effect of buprenorphine intact.

5 Surprisingly, in animal experiments we have now found that there is a limited range of ratios of buprenorphine with naloxone for which, by injection, the analgesic performance is equal to that of buprenorphine alone whilst the abstinence-precipitating effects in opiate-dependent
10 subjects are equivalent to that of naloxone alone. When the opiates such as morphine, methadone, and oxycodone are mixed with naloxone the agonist-antagonist interaction reduces the analgesic performance of the agonist and in complementary fashion reduces the antagonist performance of the naloxone.

15 There is no teaching in the prior art regarding the protection of preparations of opioids intended for sublingual administration by the incorporation of naloxone. We have found that the bioavailability of naloxone by the sublingual route is very much better (20%) than by the oral
20 route (1%) and thus the concept which was developed by others for the protection of oral opioid preparations against parenteral abuse would not be expected to apply to sublingual and buccal preparations.

However the sublingual bioavailability of buprenorphine
25 (50%) is superior to that of naloxone and since we have shown that in a limited range of dosage ratios by parenteral administration naloxone, with full bioavailability, could be combined with buprenorphine without affecting its analgesic performance, we were able to extend our findings to an

equivalent limited range of dosage ratios for sublingual and buccal administration which would achieve similar results and afford protection against parenteral misuse.

According to this invention there is provided an
5 analgesic composition in parenteral or sublingual dosage form comprising an active dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the
10 buprenorphine.

It is to be understood that the use of the terms buprenorphine and naloxone comprehend not only the bases but also their pharmaceutically acceptable salts. Particular preferred salts are the hydrochlorides.

15 It will be appreciated that the required ratio of naloxone to buprenorphine is dependent upon the proposed route of administration. Preferably the parenteral dosage form contains naloxone and buprenorphine within the weight ratio of 1:3 to 1:1 and the sublingual form within the ratio
20 1:2 to 2:1.

The ratios were determined in our laboratories according to the following methods.

In the rat tail pressure test (Green, Young, Br. J. Pharmac. Chemother., 6, 572 (1957)) the maximum
25 antinociceptive effect (ED_{90}) with buprenorphine was achieved at a dose of 0.03mg/kg, by subcutaneously administration (s.c.). The equivalent antinociceptive dose of morphine was 3.0mg/kg. These doses were selected for evaluation of the influence of co-administration of naloxone

on the antinociceptive effect of both buprenorphine and morphine. Inclusion of naloxone at the dose of 0.02mg/kg with the buprenorphine dose produced no significant antagonism (Figure 1). Increasing the naloxone content to 5 0.04 and 0.08mg/kg produced significant antagonism (Dunnett's test) of the antinociceptive effect of buprenorphine at 15 minutes and at these ratios the trend was maintained over 60 minutes.

Naloxone at all three dose levels produced significant 10 falls in the antinociceptive effect of morphine (Figure 2). These results show that buprenorphine is significantly less sensitive than morphine to the antagonist effects of naloxone. In particular a dose of 0.02mg/kg of naloxone has 15 no effect on the ED₉₀ dose of buprenorphine but it reduces by greater than 30% the antinociceptive action of the equivalent dose of morphine.

The ability to precipitate abstinence in morphine-dependent rats has been evaluated using the method of Teiger D.G., J. Pharmac. exp. Ther. 190, 408 (1974). 20 Table 1 presents the mean behavioural scores precipitated by intravenous administration of the challenge drug after 48 hour infusions of 100mg/kg/24h of morphine.

Table 1

Challenge	Dose	Mean behavioural			
		Drug	mg/kg	score	P
25	Saline		0.03	6.7	-
	Buprenorphine		0.03	11.7	NS
	Buprenorphine		0.3	14.2	NS
	Naloxone		0.02	40.8	<0.01

Table 1 (cont.)

Challenge	Dose	Mean behavioural	
<u>Drug</u>	<u>mg/kg</u>	<u>score</u>	<u>p</u>
Naloxone	0.2	63.3	<0.01
5 Buprenorphine	0.03		
+ Naloxone	0.02]	31.7	<0.05
Buprenorphine	0.3]		
+ Naloxone	0.2]	54.2	<0.01

10 Buprenorphine (0.03mg/kg or 0.3mg/kg) produced only very mild signs of withdrawal, as indicated by low mean behaviour scores. Naloxone (0.02mg/kg and 0.2mg/kg) produced rapid and intense abstinence effects which were maintained when combined with buprenorphine in a 2:3 ratio.

15 This ratio of naloxone to buprenorphine has been evaluated in analgesic studies in patients. The efficacy and safety of buprenorphine (0.3mg per patient) in combination with naloxone (0.2mg) was compared with buprenorphine (0.3mg) alone following intramuscular or intravenous administration to 162 patients with moderate to 20 severe post operative pain. Patients were assessed for pain intensity, pain relief and vital signs (pulse rate and systolic and diastolic blood pressure) at regular intervals for a six hour period after administration. The duration of analgesia was measured by recording the time to analgesic 25 remedication and all unwanted effects occurring during the assessment period were recorded. Both treatments provided good analgesia which lasted for approximately 10-12 hours. Statistical analysis of the efficacy data showed no significant difference between the two treatments for pain.

intensity, pain relief or duration of analgesia. Analysis of the unwanted effects and vital signs data also showed no significant differences between the two treatments. These results show that the buprenorphine/naloxone combination 5 provides safe and effective analgesia and there is no significant differences between the combination and buprenorphine alone with regard to efficacy.

It is preferable to formulate the compositions in unitary dosage forms i.e. physically discrete units 10 containing the appropriate amounts of buprenorphine and naloxone together with pharmaceutically acceptable diluents and/or carriers. Such unitary dosage forms for parenteral administration are suitably in the form of ampoules and for sublingual administration in the form of tablets.

15 Compositions intended for parenteral administration comprise an isotonic solution of buprenorphine and naloxone in sterile water. Conveniently the solution is made isotonic by use of dextrose and sterilised by autoclaving or by filtration through a membrane filter.

20 Compositions in the form of sublingual tablets contain soluble excipients such as lactose, mannitol, dextrose, sucrose or mixtures thereof. They will also contain granulating and disintegrating agents such as starch, binding agents such as povidone or hydroxypropyl-methyl 25 cellulose and lubricating agents such as magnesium stearate.

The compositions in unitary dosage form for parenteral administration comprises from about 0.3 to about 0.6mg buprenorphine together with an amount of naloxone such that the ratio by weight of naloxone to buprenorphine is within

the range of 1:3 to 1:1, plus a pharmaceutically acceptable carrier.

The compositions in the form of a sublingual tablet comprise from about 0.1 to about 0.4mg buprenorphine 5 together with an amount of naloxone such that the ratio by weight of naloxone to buprenorphine is within the range of 1:2 to 2:1, plus at least one pharmaceutically acceptable carrier or diluent.

The invention is illustrated by the following
10 Examples:-

Example 1

A parenteral formulation having the following composition

		mg/ml
15	Buprenorphine HCl	0.324
	Naloxone HCl	0.3
	Anhydrous dextrose	50.0
	Hydrochloric acid	to pH 4.0
	Water for injection	to 1.0 ml

20 was prepared by dissolving dextrose, buprenorphine hydrochloride and naloxone hydrochloride in that order with stirring, in about 95% batch volume of Water for Injection. The acidity of the solution was adjusted to pH 4.0 by the addition of 0.1M hydrochloric acid, and the solution was 25 made up to volume with Water for Injection. The solution was filtered through a 0.22μm membrane filter and transferred to sterilised 1ml or 2ml glass ampoules containing 1ml or 2ml of the solution containing 0.3 or 0.6mg of buprenorphine base respectively. The ampoules were

- 10 -

sealed and the product sterilised by autoclaving.

Example 2

The formulation of Example 1 was varied by using 0.15mg/ml of naloxone hydrochloride instead of 0.3mg/ml.

5 Example 3

The formulation of Example 1 was varied by using 0.20mg/ml of naloxone hydrochloride instead of 0.3mg/ml.

Example 4

A sublingual tablet formulation having the following
10 composition

	<u>mg/tablet</u>
Buprenorphine HCl	0.216
Naloxone HCl	0.2
Lactose	30.934
Mannitol	18.0
Maize starch	9.0
Povidone	1.2
Magnesium stearate	<u>0.45</u>
	60.0

20 was prepared by screening all the materials with the exception of the magnesium stearate through a 750µm sieve and blending them together. The mixed powders were then subjected to an aqueous granulation procedure and dried at 50°C. The resulting granules were forced through a 750µm
25 sieve and blended with magnesium stearate (pre-sieved through a 500µm sieve). The tablet granules were compressed to yield tablets of 5.56mm diameter and weight 60mg.

Example 5

The formulation of Example 4 was varied by using

0.4mg/tablet of naloxone hydrochloride and 30.734mg/tablet lactose.

Example 6

The formulation of Example 4 was varied by using
5 0.1mg/tablet of naloxone hydrochloride and 31.034mg/tablet lactose.



Example 7

The formulation of Example 4 was varied by using
0.108mg/tablet of buprenorphine hydrochloride, 0.1mg/tablet
10 naloxone hydrochlorite and 31.142mg/tablet lactose.

Claims

1. An analgesic composition in parenteral or sublingual dosage form comprising an active dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine.
2. A pharmaceutical composition according to Claim 1 in parenteral dosage form wherein the weights of naloxone and buprenorphine are within the ratio of 1:3 to 1:1.
3. A pharmaceutical composition according to Claim 2 in unit dosage form for parenteral administration wherein the weight of buprenorphine is between about 0.3 to about 0.6mg.
4. A pharmaceutical composition according to Claim 1 in sublingual dosage form wherein the weights of naloxone and buprenorphine are within the ratio of 1:2 to 2:1.
5. A pharmaceutical composition according to Claim 4 in unit dosage form for sublingual administration wherein the weight of buprenorphine is between about 0.1 to about 0.6mg.
6. A pharmaceutical composition in parenteral or sublingual dosage form comprising an active dose of buprenorphine and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine for use in the treatment of pain.

0144243





European Patent
Office

EUROPEAN SEARCH REPORT

0144243
Application number

EP 84 30 8459

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
X	US-A-3 493 657 (M.J.LEWENSTEIN) * Column 4, lines 14-36; claims 1-6 *	1-6	A 61 K 31/485
X	FR-A-2 137 560 (ENDO LABORATORIES INC.) * Page 7, lines 1-28; claims 1-4 *	1-6	
D,X	FR-A-2 101 191 (BRISTOL-MYERS COMPANY) * Page 23, line 1 - page 24, line 8; claims 1-4 *	1-6	
X	CHEMICAL ABSTRACTS, Vol.94, No.19, May 11, 1981, page 55, column 1, abstract no. 150268y, COLUMBUS, OHIO, .(US), M.J.RANCE et al.: "Biphasic dose response to buprenorphine in the rat tail flick assay: effect of naloxone pretreatment". & Endog. Exog. Opiate Agonists Antagonists, Proc. Int. Narc. Res. Club Conf. 1979 (Pub.1980) 387-90 * Abstract *	1-6	A 61 K
---		-/-	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	11-03-1985	Mlle BRINKMANN	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone	T : theory or principle underlying the invention		
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date		
A : technological background	D : document cited in the application		
O : non-written disclosure	L : document cited for other reasons		
P : intermediate document	& : member of the same patent family, corresponding document		



European Patent
Office

EUROPEAN SEARCH REPORT

0144243
Application number

EP 84 30 8459

- Page 2 -

DOCUMENTS CONSIDERED TO BE RELEVANT																		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)															
X	<p>CHEMICAL ABSTRACTS, Vol.90, No.19 May 7, 1979, page 37, column 1, abstract no. 145726j, COLUMBUS, OHIO, (US).</p> <p>L.MANARA et al.: "Rat brain levels and subcellular distribution of in vivo administered buprenorphine: effect of naloxone".</p> <p>& Dev. Neurosci. (Amsterdam) 1978, 4(Charact. Funct. Opioids) 225-6.</p> <p>* Abstract *</p> <p>-----</p>	1-6																
TECHNICAL FIELDS SEARCHED (Int. Cl.4)																		
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search</td> <td>Date of completion of the search</td> <td>Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>11-03-1985</td> <td>Mlle BRINKMANN</td> </tr> <tr> <td colspan="3">CATEGORY OF CITED DOCUMENTS</td> </tr> <tr> <td colspan="3"> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document </td> </tr> <tr> <td colspan="3"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document </td> </tr> </table>				Place of search	Date of completion of the search	Examiner	THE HAGUE	11-03-1985	Mlle BRINKMANN	CATEGORY OF CITED DOCUMENTS			X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		
Place of search	Date of completion of the search	Examiner																
THE HAGUE	11-03-1985	Mlle BRINKMANN																
CATEGORY OF CITED DOCUMENTS																		
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document																		
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document																		